Cross Timothy J S, Bagot Catherine, Portmann Bernard, Wendon Julia, Gillett D
Department of Haematology, Kent and Sussex Hospital, Mount Ephraim, Tunbridge Wells, Kent, England.
Am J Hematol. 2006 Mar;81(3):189-92. doi: 10.1002/ajh.20486.
A 46-year-old patient diagnosed with chronic myeloid leukemia in whom cytogenetic and molecular remission had never been achieved was commenced on Imatinib Mesylate (Gleevec, Novartis Pharmaceuticals Corp., East Hanover, NJ). After 18 months of treatment, she developed abnormal liver function tests and subsequently acute liver failure, requiring transfer to the regional liver unit. The patient proceeded to liver transplantation but later died. The explanted liver had histological features of severe hepatic necrosis. This is the first case described of fatal hepatic necrosis in a patient who has have been on long-term imatinib therapy. This may have implications for long-term use of the drug and emphasizes the need for regular monitoring of liver function.
一名46岁被诊断为慢性髓性白血病且从未实现细胞遗传学和分子学缓解的患者开始接受甲磺酸伊马替尼（格列卫，诺华制药公司，新泽西州东哈嫩）治疗。治疗18个月后，她出现肝功能检查异常，随后发展为急性肝衰竭，需要转至地区肝病科。该患者接受了肝移植，但后来死亡。移植的肝脏具有严重肝坏死的组织学特征。这是首例描述的长期接受伊马替尼治疗患者发生致命性肝坏死的病例。这可能对该药物的长期使用有影响，并强调了定期监测肝功能的必要性。
